phenytoin sodium BE study [Regulatives / Guidelines]

posted by jagankm  – 2012-04-24 13:54 (5177 d 12:04 ago) – Posting: # 8459
Views: 5,881

Dear All,

WE are generic pharmaceuticals developing phenytoin sodium capsules in the concentration of 25 -300mg (dose proportional)for Uk submission.
The query is regarding BE study strength.

as phenytoin is nonlinear pharmacokinetic drug. As per EMEA guidance we can show bioequivalence for higher strength (300 mg) and can apply Biowaiver for remaining strenghts.
we are in ambiquity to decide correct BE strength. kindly advice.

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,572 registered users;
325 visitors (0 registered, 325 guests [including 36 identified bots]).
Forum time: 01:58 CEST (Europe/Vienna)

Don’t compromise yourself.
You are all you’ve got.    Janis Joplin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5